Thomas K Eigentler
Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Gaissler A, Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, Spreuer J, Amaral T, Wagner N, Klein R, Meier F, Garbe C, Eigentler T, Pawelec G, Claassen M, Weide B, Hadrup S, Wistuba-Hamprecht K. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. Front Immunol 2022; 13:906352.
Jul 7, 2022Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade.
Jul 7, 2022Front Immunol 2022; 13:906352
Gaissler Andrea, Meldgaard Trine Sundebo, Heeke Christina, Babaei Sepideh, Tvingsholm Siri Amanda, Bochem Jonas, Spreuer Janine, Amaral Teresa, Wagner Nikolaus, Klein Reinhild, Meier Friedegund, Garbe Claus, Eigentler Thomas K, Pawelec Graham, Claassen Manfred, Weide Benjamin, Hadrup Sine Reker, Wistuba-Hamprecht Kilian
Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Gassenmaier M, Lenders M, Forschner A, Leiter U, Weide B, Garbe C, Eigentler T, Wagner N. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors. Target Oncol 2021; 16:197-205.
Feb 8, 2021Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
Feb 8, 2021Target Oncol 2021; 16:197-205
Gassenmaier Maximilian, Lenders Max M, Forschner Andrea, Leiter Ulrike, Weide Benjamin, Garbe Claus, Eigentler Thomas K, Wagner Nikolaus
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021; 9
Jan 1, 2021Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Jan 1, 2021J Immunother Cancer 2021; 9
Wagner Nikolaus, Schraag Amadeus, Klumpp Bernhard, Hoetzenecker Wolfram, Berking Carola, Richtig Erika, Ziemer Mirjana, Mangana Johanna, Terheyden Patrick, Loquai Carmen, Nguyen Van Anh, Gebhardt Christoffer, Meier Friedegund, Diem Stefan, Cozzio Antonio, Flatz Lukas, Röcken Martin, Garbe Claus, Gassenmaier Maximilian, Weide Benjamin, Leiter Ulrike, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, André Fiona, Dudda Milena, Ring Natalie, Ebel Chiara, Stäger Ramon, Zellweger Caroline, Lang Roland, Paar Michael, Gussek Philipp, Richtig Georg, Stürmer Suzan H, Kimeswenger Susanne, Oellinger Angela, Forschner Andrea, Eigentler Thomas K
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Bochem J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. J Immunother Cancer 2021; 9
Jan 1, 2021Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy
Jan 1, 2021J Immunother Cancer 2021; 9
Bochem Jonas, Meier Friedegund, Terheyden Patrick, Königsrainer Alfred, Garbe Claus, Flatz Lukas, Pawelec Graham, Eigentler Thomas K, Löffler Markus W, Weide Benjamin, Niessner Heike, Sinnberg Tobias, Zelba Henning, Spreuer Janine, Amaral Teresa, Gaissler Andrea, Pop Oltin, Thiel Karolin, Yurttas Can, Soffel Daniel, Forchhammer Stephan, Wistuba-Hamprecht Kilian
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2020; 70:1089-1099.
Oct 28, 2020Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors
Oct 28, 2020Cancer Immunol Immunother 2020; 70:1089-1099
Winter Johanna, Eigentler Thomas K, Garbe Claus, Röcken Martin, Cozzio Antonio, Flatz Lukas, Purde Mette-Triin, Weide Benjamin, Leiter Ulrike, Forschner Andrea, Gassenmaier Maximilian, Lenders Max M, Wagner Nikolaus
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
Gassenmaier M, Garbe C, Schaller M, Wagner N, Bösmüller H, Niessner H, Sinnberg T, Kosnopfel C, Ikenberg K, Eigentler T, Fehrenbacher B, Rentschler M, Röcken M. Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors. Am J Pathol 2020; 190:2155-2164.
Jul 15, 2020Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors
Jul 15, 2020Am J Pathol 2020; 190:2155-2164
Gassenmaier Maximilian, Garbe Claus, Schaller Martin, Wagner Nikolaus, Bösmüller Hans, Niessner Heike, Sinnberg Tobias, Kosnopfel Corinna, Ikenberg Kristian, Eigentler Thomas K, Fehrenbacher Birgit, Rentschler Maximilian, Röcken Martin
Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Wagner N, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, Eigentler T. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. Australas J Dermatol 2020; 61:e310-e318.
Feb 12, 2020Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy
Feb 12, 2020Australas J Dermatol 2020; 61:e310-e318
Wagner Nikolaus, Luttermann Felix, Gassenmaier Maximilian, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Wagner N, Forschner A, Leiter U, Garbe C, Eigentler T. S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. Br J Cancer 2018; 119:339-346.
Jun 28, 2018S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
Jun 28, 2018Br J Cancer 2018; 119:339-346
Wagner Nikolaus, Forschner Andrea, Leiter Ulrike, Garbe Claus, Eigentler Thomas K